Astera Labs (ALAB): Revenue +104%, A Clean Beat — And Our Call Is SELL. Is ALAB Stock a Buy?

Astera Labs, Inc. (ALAB) Q2 2026 — Reported Aug 4, 2026 AFTER the close (release 4:05pm ET) for Q2 2026, the quarter ended June 30. Revenue $392.4M, +104.5% YoY and +27.3% QoQ, vs ~$360M consensus. Non-GAAP EPS $0.80 vs $0.64 expected. GAAP EPS $0.83. Q3 guide $540-560M. ALAB closed $361.67, +12.65% - but that move is PRE-print. Astera Labs printed a record quarter and the operating beat is real: revenue +104%, non-GAAP operating margin 39.1%, Scorpio X in volume a quarter early. Then we read the cash-flow statement: first-half revenue doubled to $700.8M and free cash flow FELL, $139.3M to $134.2M. After $112.9M of stock comp, owner earnings for the half were $21.3M - against a $62B market cap. THE CALL: SELL (3/5, AN OUTSTANDING QUARTER AT A PRICE THAT NEEDS NINE MORE) — base-case value ~$186.0 vs ~$361.67 today. KEY METRICS: - CALL: SELL 3/5, fair value ~$185 vs $361.67 - about 49% BELOW the price. Nine-year owner-earnings DCF: 2027E revenue $3,150M at 71.5% gross margin less 41.5 pts of opex = $945M GAAP operating income (stock comp inside), less 14% cash tax, less capex and $156M of working capital = $625M owner FCF; revenue compounding 23%/yr to $12.5B by 2035 at a 39% terminal margin, 10.5% discount = $35.0B enterprise, plus $1.25B net cash, over ~195M shares = $186. Bear $87, bull $320. - GAAP EPS $0.83 BEAT NON-GAAP EPS $0.80 - a warning, not a win. Pre-tax income $102.8M, then an income tax BENEFIT of $50.3M: a MINUS 48.9% rate. Tax that at the 12% the company uses on its own non-GAAP line and net income is ~$90.5M, or ~$0.49 a share - so ~$0.34 of the GAAP headline is tax, not operations. The $0.80 non-GAAP beat IS real ($153.5M operating income, 39.1% margin). Q3 guides GAAP EPS $0.87-0.92 BELOW non-GAAP $1.16-1.21 - the benefit is not expected to repeat. - REVENUE DOUBLED AND FREE CASH FLOW WENT DOWN. H1 2026: revenue $700.8M (+99%), OCF $162.3M, capex $28.1M, FCF $134.2M. H1 2025 on half the revenue: FCF $139.3M. That is -3.7%. Cause is a ramp, not a fraud: receivables $83.2M to $192.5M (~45 days), inventory $59.0M to $113.8M (~99 days of COGS), prepaids tripled - $204M of working capital consumed in six months. Subtract H1 stock comp of $112.9M and owner earnings were $21.3M against a $61.99B market cap. - THE INFLECTION IS MARGIN-DILUTIVE. Non-GAAP gross margin 76.4% (Mar) to 73.7% (Jun) to a guided 72.0% (Sep) - 440bp in two quarters, as Scorpio X switches (more silicon than retimers) become the largest line. The bull case survives: 72% of a $550M midpoint = $396M gross profit, less $156-160M non-GAAP opex = ~$238M operating profit, a 43.3% margin UP from 39.1%. Revenue +40%, gross profit +37%, operating profit +55%, opex only +16%. - CONCENTRATION: the Q1 2026 10-Q shows five direct customers at 29/21/16/12/12% of revenue - 90% in five names, the largest up from 12% a year earlier. 'Warrants contra revenue' was $12.3M in H1 vs $2.1M - the Amazon warrant, netted off reported revenue. Cash + securities $1.25B, ZERO debt. STREET: consensus Buy (13/5/0) but the $301.82 average target and $275 median sit BELOW the $361.67 close, the average by 16.5%. We DIFFER. What to watch: Changes our mind UP: FCF above 20% of revenue for two straight quarters, or the largest customer back under 20%. Confirms the bear: gross margin guided below 70%, or receivable days past 60. We would start buying under $200. We are NOT recommending shorting it. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.